We are live on ! Find out more
IMVT icon

Immunovant

112 hedge funds and large institutions have $197M invested in Immunovant in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 44 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,192% more call options, than puts

Call options by funds: $6.87M | Put options by funds: $532K

1.07% more ownership

Funds ownership: 32.91%33.98% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5% less funds holding

Funds holding: 118112 (-6)

14% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 44

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

39% less capital invested

Capital invested by funds: $322M → $197M (-$124M)

Holders
112
Holders Change
-6
Holders Change %
-5.08%
% of All Funds
1.77%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
38
Reduced
44
Closed
19
Calls
$6.87M
Puts
$532K
Net Calls
+$6.34M
Net Calls Change
-$15.5M
Name Holding Trade Value Shares
Change
Change in
Stake
FRM
126
Fox Run Management
Connecticut
-$92K -10,803 Closed
Marshall Wace
127
Marshall Wace
United Kingdom
-$71K -8,316 Closed
Simplex Trading
128
Simplex Trading
Illinois
-$25K -4,019 Closed
S
129
SignatureFD
Georgia
-$7K -840 Closed
PA
130
Parallel Advisors
California
-$3K -382 Closed
UB
131
UMB Bank
Missouri
-$1K -141 Closed

IMVT Hedge Fund Activity: Q1 2022 in Review

112 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2022, worth a combined $197M — down 39% from $322M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of IMVT and 13 opened new positions — a net loss of 6 holders — while 44 trimmed existing stakes and 38 added.

The largest buyer was Deep Track Capital, adding an estimated $15.3M. The largest seller was State Street, cutting an estimated $12.1M.

  • 112 institutional investors held Immunovant (IMVT) as of Q1 2022, down from 118 in Q4 2021.
  • Funds reported $197M of Immunovant stock for Q1 2022, down 39% quarter-over-quarter.
  • 13 funds opened new Immunovant positions in Q1 2022 and 19 closed out, a net change of -6 holders.
  • The largest Immunovant buyer in Q1 2022 was Deep Track Capital, an estimated $15.3M added.
  • The largest Immunovant seller in Q1 2022 was State Street, an estimated $12.1M sold.

Based on aggregated 13F filings for Q1 2022.